Our Mission

Improving lives after lung transplant

Company

Canvas Pharmaceuticals is a clinical-stage biopharmaceutical company developing inhalational therapies for complex pulmonary diseases.

We are committed to patients with unmet needs and have two clinical stage product candidates with favorable efficacy, safety and tolerability data:

• Tacrolimus Inhalation Powder: Phase 2 asset, lead development candidate
• Voriconazole Inhalation Powder: Phase 3 ready asset, out-licensing/partnering candidate

Our initial focus is on the development of Tacrolimus Inhalation Powder for prevention of acute rejection and maintenance of lung allograft after lung transplantation.

Tacrolimus delivered via the oral route is the standard of care calcineurin inhibitor for prevention of rejection and considered a narrow therapeutic index drug. It is used in greater than 90% of lung transplant patients. With poor and variable gastrointestinal absorption, oral tacrolimus leads to erratic tacrolimus systemic exposures with high peak to trough swings, resulting in toxicities and loss of efficacy, thus contributing to approximately 50% mortality, 5 years post-transplant.

Tacrolimus Inhalation Powder is a novel, patented dry powder formulation of tacrolimus, delivered via an easy-to-use dry powder inhaler. With direct-to-lung delivery and improved pharmacokinetic properties, Tacrolimus Inhalation Powder has the potential to widen the therapeutic window of tacrolimus, increase efficacy and decrease toxicities to improve outcomes.

Tacrolimus Inhalation Powder has orphan drug designation.

Technology

Canvas Pharmaceuticals holds over 60 U.S. and ex-U.S. patents and patent applications with patent term extending to 2043.

Thin Film Freezing Technology enables the generation of dry powder formulations optimized for inhalational delivery

Tacrolimus Inhalation Powder delivery via an easy-to-use dry powder inhaler